Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults

San Segundo, David; Comins-Boo, Alejandra; Irure-Ventura, Juan; Renuncio-García, Mónica; Roa-Bautista, Adriel; González-López, Elena; Merino-Fernández, David; Lamadrid-Perojo, Patricia; Alonso-Peña, Marta; Ocejo-Vinyals, Javier Gonzalo; Gutiérrez-Larrañaga, Maria; Guiral-Foz, Sandra; López-Hoyos, Marcos

Vaccine efficacy is based on clinical data. Currently, the assessment of immune response after SARS-CoV-2 vaccination is scarce. A total of 52 healthcare workers were immunized with the same lot of BNT162b2 vaccine. The immunological response against the vaccine was tested using a T-specific assay based on the expression of CD25 and CD134 after stimulation with anti-N, -S, and -M specific peptides of SARS-CoV-2. Moreover, IgG anti-S2 and -RBD antibodies were detected using ELISA. Furthermore, the cell subsets involved in the response to the vaccine were measured in peripheral blood by flow cytometry. Humoral-specific responses against the vaccine were detected in 94% and 100% after the first and second doses, respectively. Therefore, anti-S T-specific responses were observed in 57% and 90% of the subjects after the first and second doses of the vaccine, respectively. Thirty days after the second dose, significant increases in T helper 1 memory cells (p < 0.001), peripheral memory T follicular helper (pT(FH)) cells (p < 0.032), and switched memory (p = 0.005) were observed. This study describes the specific humoral and cellular immune responses after vaccination with the new mRNA-based BNT162b2 vaccine. A mobilization of T(FH) into the circulation occurs, reflecting a specific activation of the immune system.